Non-Invasive Drug-Device Treatment Aims to Target Brain Cancers Selectively, Turning them from Lethal Diseases into Manageable Conditions: Led by Experts with Decades of Experience Developing and Commercializing Drug-Device Systems in Photodynamic…
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and precision medicines, today announced that positive clinical data based on a…
ORIENT-32 is the first randomized Phase 3 study reporting the efficacy and safety of an anti-PD-1 antibody-based combination therapy versus sorafenib as the first-line treatment in patients with advanced unresectable hepatocellular carcinoma (HCC).
FLASH therapy delivers radiation at ultra-high dose rates up to 100 times faster compared to conventional radiation therapy. The first patient in the world to participate in a clinical trial of FLASH therapy has been enrolled.
This first FDA clearance represents a significant milestone for AI Metrics, where researchers have been seeking new ways to use CT scans for virtual liver biopsy.
OncoQuest Pharmaceuticals, Inc., has begun dosing patients in the USA for the Phase 3 clinical trial of its immunotherapeutic drug candidate oregovomab.